Esophageal Cancer Stage IIIC

Reviewed by Oncology Team, HealOnco | Last updated: 2026-04

5-year survival: <10%

5-year survival rate

Stage IIIC

T4bN0–2M0. Tumor invades adjacent structures (aorta, vertebra, trachea). Highly advanced locoregional disease.

What Stage IIIC Means

T4bN0–2M0. Tumor invades adjacent structures (aorta, vertebra, trachea). Highly advanced locoregional disease.

Treatment Approach for Stage IIIC

Palliative CRT or chemotherapy. Supportive care and symptom management prioritized.

Survival Rates and Prognosis

The 5-year survival rate for esophageal cancer at Stage IIIC is approximately 5-year survival: <10%. Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.

Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.

How Other Stages Compare

Stage	5-Year Survival	Treatment
Stage I	5-year survival: 40–50%	Endoscopic resection if T1a, N0. Surgery (esophagectomy) if T1b–2….
Stage IIA	5-year survival: 25–35%	Surgery with potential neoadjuvant chemotherapy/RT. Neoadjuvant CROSS protocol…
Stage IIB	5-year survival: 20–30%	Neoadjuvant chemotherapy/RT followed by esophagectomy. Consider induction…
Stage IIIA	5-year survival: 15–25%	Neoadjuvant CROSS protocol (carboplatin + paclitaxel + 50.4 Gy RT) followed by…
Stage IIIB	5-year survival: 10–20%	Neoadjuvant CRT with 50.4–60 Gy. Surgery if resectable post-treatment….
Stage IVA	5-year survival: <5%	Palliative chemotherapy (FOLFOX or platinum-fluorouracil). Endoscopic stent for…
Stage IVB	Median OS: 6–12 months with treatment	Palliative chemotherapy (FOLFOX, carboplatin-gemcitabine) or immunotherapy…